Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients

BACKGROUND: Natalizumab is an effective treatment in relapsing-remitting multiple sclerosis (MS). Mainly because of the risk of progressive multifocal leukoencephalopathy (PML), a substantial proportion of John Cunningham (JC) virus–positive patients switch to fingolimod. Previous reports show a cle...

Descripción completa

Detalles Bibliográficos
Autores principales: Leurs, Cyra E, van Kempen, Zoé LE, Dekker, Iris, Balk, Lisanne J, Wattjes, Mike P, Rispens, Theo, Uitdehaag, Bernard MJ, Killestein, Joep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Original Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174622/
https://www.ncbi.nlm.nih.gov/pubmed/28823223
http://dx.doi.org/10.1177/1352458517726381

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174622/
https://www.ncbi.nlm.nih.gov/pubmed/28823223
http://dx.doi.org/10.1177/1352458517726381

Ejemplares similares